Kurse werden geladen...
Prognose
Kaufen | 3 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives. The patented compounds were.» Mehr auf businesswire.com
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced positive preclinical results for its lead neuroplastogen drug candidate, EB-003, in the Open Space Forced Swim Test, a preclinical mouse model of severe depression and despair. The Open Space Forced Swim Test, a wel.» Mehr auf businesswire.com
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules discovered to offer potential to address neurodegenerative disease. If c.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 0,00 | 100,00% |
Nettoeinkommen | −2,02 Mio | 11,28% |
EBITDA | −1,95 Mio | 12,14% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 2,66 Mio€ |
Anzahl Aktien | 2,47 Mio |
52 Wochen-Hoch/Tief | 150,33€ - 0,88€ |
Dividenden | Nein |
Beta | 0,32 |
KGV (PE Ratio) | −0,24 |
KGWV (PEG Ratio) | 0,04 |
KBV (PB Ratio) | 0,57 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Name | Enveric Biosciences Aktie |
CEO | Dr. Joseph Edward Tucker Ph.D. |
Mitarbeiter | 5 |
Assets entdecken
Shareholder von Enveric Biosciences Aktie investieren auch in folgende Assets